Thelansis

 Hereditary Angioedema (HAE) is a rare genetic disorder marked by the recurrent occurrence of transient subcutaneous and submucosal edemas, leading to swelling and abdominal pain. This condition is characterized by three distinct types, each with its prevalence and clinical manifestations. The hallmark symptoms of HAE include recurrent and unpredictable episodes of swelling in various body parts, such as the face, extremities, genitals, and gastrointestinal tract. Abdominal pain is a common manifestation and can be severe, often leading to unnecessary surgeries due to the misdiagnosis of the acute abdomen. While there is no cure for HAE, effective management strategies aim to control symptoms and reduce the frequency and severity of attacks. Medications such as C1-INH replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors have shown efficacy in treating and preventing HAE attacks. HAE is estimated to impact approximately 1 in 50,000 individuals, making it a...

 Hereditary angioedema (HAE) is a genetic disease characterized by the occurrence of transitory and recurrent subcutaneous and/or submucosal edemas resulting in swelling and/or abdominal pain. Three types of HAE have been described. ·        Hereditary Angioedema (HAE) is estimated to affect 1 in 50,000 people. Type I is the most common, accounting for 85 per cent of cases. Type II occurs in 15 per cent of cases, and type III is very rare Thelansis’s “Hereditary Angioedema (HAE) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Angioedema (HAE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China)....